Retension Pharmaceuticals IPO priced at $12, raising $45 million
As seen on the 24/7 Wall St. homepage on October 9, 2026.
Priced at $12, raising roughly $45 million
Retension Pharmaceuticals priced at $12 a share, locking in about $45 million from 3.75 million shares with Leerink Partners and Guggenheim Securities leading the deal. Trading opens with terms set, so the first tick is the only entry point left.
Continue ReadingShow less
Retension Pharmaceuticals priced its IPO at $12 per share, raising approximately $45 million. Pricing is locked in, so the opening trade on day one is the only entry point left for investors.
Leerink Partners and Guggenheim Securities are leading the deal, a pairing that signals a biotech-focused institutional bookbuild. Both banks are active in life sciences capital markets, which typically means the initial allocation went primarily to institutional buyers rather than retail investors.
The $12 price is fixed and the shares are sold, so the first tick in open trading sets the premium or discount the market assigns. Whether the stock holds above that price is the clearest near-term read on demand.
The SEC filing tied to this offering carries the full prospectus: use of proceeds, risk factors, and the company's pipeline and financial condition. Read it before taking a position.